CT-Based Radiogenomic Prediction of ICAM1 and RAET1E as Biomarkers of NK Cytotoxicity in Clear Cell Renal Cell Carcinoma

• by Ma, Xinwei , Yang, Jiao , Qian, Xusheng , Dou, Xin , Ji, Shiliang , Dai, Yakang , Yang, Yi , Wang, Yi , Zhu, Jianbing

• May 20, 2026

Consensus Guidelines for the Management of Locally Advanced and Metastatic Renal Cell Carcinoma by the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology for 2025

• by Darren M. C. Poon, Philip W. K. Kwong, Samson Y. S. Chan, Brian S. H. Ho, Martin H. C. Lam, K. S. Law, Angus K. C. Leung, Clarence L. H. Leung, David K. W. Leung, W. K. Ma, Barry B. W. Wo, Kenneth C. W. Wong, Philip Y. Wu, Peter K. F. Chiu

• April 23, 2026

Dana-Farber Research News 04.01.2026

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 1 - 15.

• by

• April 1, 2026

• 37 min

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.

• July 1, 2026

• 1 min